Lifecore Biomedical (LFCR) Q3 2025 earnings summary

Executive summary

• Achieved $35.2M in Q3 FY2025 revenue, down 2% year-over-year, mainly due to lower CDMO sales and project timing, partially offset by HA manufacturing growth and pricing initiatives.

• Net loss for Q3 FY2025 was $14.8M, compared to net income of $15.6M in the prior year, which included a one-time $21M non-cash gain.

• Adjusted EBITDA for Q3 FY2025 was $5.7M, down from $6.4M year-over-year, reflecting lower gross profit and inventory write-offs.

• Multiple new and expanded customer agreements were signed, including a major project with a multinational pharma client, supporting business development and operational improvements.

• Transitioned to a standalone CDMO with best-in-class technical capabilities, expanded capacity, and completed leadership transition.

Financial highlights

• Q3 FY2025 revenues were $35.2M, down 2% year-over-year; nine-month revenues were $92.4M, up 2%.

• Q3 gross profit was $9.8M (28.0% margin), down from $11.9M (33.3%) year-over-year; nine-month gross profit was $26.3M (28.5% margin), up from $24.6M (27.2%).

• Q3 net loss was $14.8M ($0.47 per diluted share); nine-month net loss was $37.6M ($1.24 per share), both impacted by one-time non-cash gains in the prior year.

• Adjusted EBITDA for Q3 FY2025 was $5.7M; for nine months, $10.4M, both down year-over-year.

• Cash and cash equivalents at quarter-end were $5.4M, with $25.5M available under the revolving credit facility.

Outlook and guidance

• FY2025 revenue guidance reiterated at $126.5M–$130M, with Adjusted EBITDA expected between $19M–$21M.

• Net loss for FY2025 now estimated at $38.6M–$36.6M, reflecting higher legal, interest, and reorganization expenses.

• Strategy targets a 12% revenue CAGR and EBITDA margins over 25% in the coming years, with long-term revenue potential up to $300M.

• Company expects to remain cash flow positive from operations in the second half and potentially free cash flow neutral or slightly positive.

• Management expects to record a $2.5M gain in Q4 FY25 from a lease obligation settlement.